4D Molecular Therapeutics (FDMT) News Today $4.64 -0.03 (-0.64%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$4.81 +0.17 (+3.66%) As of 02/21/2025 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesShares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the ten ratings firms that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, two have given a hoFebruary 20 at 4:27 AM | marketbeat.com4D Molecular Therapeutics (NASDAQ:FDMT) Receives "Sell (D-)" Rating from Weiss RatingsFebruary 20 at 3:47 AM | americanbankingnews.com4D Molecular Therapeutics' (FDMT) Sell (D-) Rating Reiterated at Weiss RatingsWeiss Ratings restated a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a report on Wednesday.February 20 at 2:36 AM | marketbeat.com4DMT to Participate in Upcoming Investor ConferencesFebruary 19 at 8:00 AM | globenewswire.com4D Molecular Therapeutics: A Smart Bet On Long-Term VEGF SuppressionFebruary 18, 2025 | seekingalpha.com144,743 Shares in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Acquired by Peapod Lane Capital LLCPeapod Lane Capital LLC purchased a new stake in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 144,743 shares of the company's stock, valued at approximately $806,000.February 13, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMTFebruary 11, 2025 | prnewswire.com4D Molecular Therapeutics (NASDAQ:FDMT) Given New $30.00 Price Target at Chardan CapitalChardan Capital lowered their target price on 4D Molecular Therapeutics from $39.00 to $30.00 and set a "buy" rating on the stock in a research note on Tuesday.February 11, 2025 | marketbeat.com4D Molecular Therapeutics (FDMT) Gets a Buy from RBC CapitalFebruary 10, 2025 | markets.businessinsider.comH.C. Wainwright maintains buy on 4D Molecular Therapeutics stockFebruary 10, 2025 | msn.comA Glimpse Into The Expert Outlook On 4D Molecular Therapeutics Through 9 AnalystsFebruary 10, 2025 | benzinga.comHC Wainwright Reaffirms Buy Rating for 4D Molecular Therapeutics (NASDAQ:FDMT)HC Wainwright restated a "buy" rating and set a $36.00 price target on shares of 4D Molecular Therapeutics in a report on Monday.February 10, 2025 | marketbeat.com4D Molecular Therapeutics (FDMT) Receives a Buy from BarclaysFebruary 10, 2025 | markets.businessinsider.com4D Molecular Therapeutics Reports Positive Interim Data From Phase 2b Trial For Wet AMDFebruary 9, 2025 | markets.businessinsider.com4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration ProgramFebruary 8, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMTFebruary 4, 2025 | prnewswire.comWeiss Ratings Reaffirms Sell (D-) Rating for 4D Molecular Therapeutics (NASDAQ:FDMT)Weiss Ratings reaffirmed a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a research note on Saturday.February 4, 2025 | marketbeat.com4DMT Announces Corporate Webcast to Review Interim 52-week Results from the Phase 2b Cohort of PRISM in a Broad Wet AMD PopulationJanuary 29, 2025 | markets.businessinsider.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMTJanuary 28, 2025 | prnewswire.com4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Given Consensus Recommendation of "Moderate Buy" by Analysts4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) has been given a consensus rating of "Moderate Buy" by the eleven analysts that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating and eiJanuary 26, 2025 | marketbeat.comH.C. Wainwright Reaffirms Their Buy Rating on 4D Molecular Therapeutics (FDMT)January 22, 2025 | markets.businessinsider.comCantor Fitzgerald Estimates FDMT FY2025 Earnings4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of 4D Molecular Therapeutics in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer forecastsJanuary 22, 2025 | marketbeat.comAssenagon Asset Management S.A. Sells 889,884 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)Assenagon Asset Management S.A. cut its stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) by 57.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 653,530 shares of the company's stocJanuary 22, 2025 | marketbeat.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMTJanuary 21, 2025 | prnewswire.comFDMT stock touches 52-week low at $4.48 amid market challengesJanuary 21, 2025 | msn.com4D Molecular Therapeutics' (FDMT) "Sell (D-)" Rating Reaffirmed at Weiss RatingsWeiss Ratings restated a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a research report on Saturday.January 19, 2025 | marketbeat.comWhat is HC Wainwright's Estimate for FDMT FY2029 Earnings?4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) - Investment analysts at HC Wainwright issued their FY2029 earnings per share estimates for shares of 4D Molecular Therapeutics in a research report issued on Monday, January 13th. HC Wainwright analyst M. Caufield forecasts that the comJanuary 15, 2025 | marketbeat.comResearch Analysts Issue Forecasts for FDMT FY2024 Earnings4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) - Analysts at Leerink Partnrs lifted their FY2024 EPS estimates for 4D Molecular Therapeutics in a research report issued on Monday, January 13th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will post earnings ofJanuary 15, 2025 | marketbeat.com4D Molecular Therapeutics (NASDAQ:FDMT) Price Target Lowered to $27.00 at Leerink PartnersLeerink Partners decreased their price objective on shares of 4D Molecular Therapeutics from $31.00 to $27.00 and set an "outperform" rating on the stock in a research note on Monday.January 13, 2025 | marketbeat.com4D Molecular Therapeutics (NASDAQ:FDMT) Given New $6.00 Price Target at Morgan StanleyMorgan Stanley decreased their price target on shares of 4D Molecular Therapeutics from $8.00 to $6.00 and set an "underweight" rating on the stock in a research note on Monday.January 13, 2025 | marketbeat.com4D Molecular Therapeutics' (FDMT) Buy Rating Reaffirmed at HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $36.00 price objective on shares of 4D Molecular Therapeutics in a report on Monday.January 13, 2025 | marketbeat.com4D Molecular Therapeutics (NASDAQ:FDMT) Stock Rating Lowered by BMO Capital MarketsBMO Capital Markets downgraded shares of 4D Molecular Therapeutics from an "outperform" rating to a "market perform" rating and cut their price objective for the stock from $40.00 to $15.00 in a research report on Monday.January 13, 2025 | marketbeat.comBarclays Sticks to Their Buy Rating for 4D Molecular Therapeutics (FDMT)January 12, 2025 | markets.businessinsider.comCautious Outlook for 4D Molecular Therapeutics Amid Competitive Challenges and Safety ConcernsJanuary 11, 2025 | markets.businessinsider.comBuy Rating Reiterated for 4D Molecular Therapeutics Amid Strategic Advancements and Undervalued Commercial ProspectsJanuary 11, 2025 | markets.businessinsider.comCautious Outlook for 4D Molecular Therapeutics Amid Limited Therapy Durability and Competitive PressuresJanuary 10, 2025 | markets.businessinsider.com4DMT Announces Positive Interim Data from 4D-150 SPECTRA Clinical Trial in DME and Alignment with FDA on Registrational PathJanuary 10, 2025 | finance.yahoo.com4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD & DME and 4D-710 in CF and Extends Cash RunwayJanuary 10, 2025 | finance.yahoo.com4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Given Consensus Recommendation of "Moderate Buy" by BrokeragesShares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) have earned a consensus rating of "Moderate Buy" from the eleven ratings firms that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, oJanuary 1, 2025 | marketbeat.comFmr LLC Sells 1,012,123 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)Fmr LLC reduced its position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) by 99.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 4,100 shares of the company's stock after selling 1,012,1December 26, 2024 | marketbeat.com4D Molecular Therapeutics' SWOT analysis: gene therapy stock faces pivotal yearDecember 18, 2024 | uk.investing.comPromising Prospects for 4D-150 in wAMD Treatment Amidst Competition and Investor AnticipationDecember 18, 2024 | markets.businessinsider.comBank of America Lowers 4D Molecular Therapeutics (NASDAQ:FDMT) Price Target to $46.00Bank of America cut their price objective on 4D Molecular Therapeutics from $79.00 to $46.00 and set a "buy" rating for the company in a report on Wednesday.December 18, 2024 | marketbeat.com4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Sees Significant Growth in Short Interest4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) saw a significant increase in short interest in November. As of November 30th, there was short interest totalling 8,520,000 shares, an increase of 8.8% from the November 15th total of 7,830,000 shares. Based on an average trading volume of 894,400 shares, the short-interest ratio is currently 9.5 days.December 17, 2024 | marketbeat.com4DMT Announces Landmark Publication of 4D-150 Preclinical Data for the Treatment of Neovascular Retinopathies in IOVSDecember 16, 2024 | finance.yahoo.com4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Given Average Recommendation of "Moderate Buy" by AnalystsShares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) have been given a consensus rating of "Moderate Buy" by the ten analysts that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has assiDecember 7, 2024 | marketbeat.comWalleye Capital LLC Takes $912,000 Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)Walleye Capital LLC acquired a new stake in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 84,322 shares of the company's stock, valued at approximaDecember 7, 2024 | marketbeat.comRedmile Group LLC Increases Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)Redmile Group LLC raised its stake in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) by 17.6% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 1,262,090 shares of the company's stock after buyDecember 5, 2024 | marketbeat.com4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Stock Holdings Trimmed by Healthcare of Ontario Pension Plan Trust FundHealthcare of Ontario Pension Plan Trust Fund lessened its position in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) by 35.0% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 459,00November 30, 2024 | marketbeat.comBraidwell LP Buys 855,990 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)Braidwell LP boosted its stake in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) by 231.7% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,225,448 shares of the company's stock after acquiringNovember 29, 2024 | marketbeat.com Get 4D Molecular Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FDMT and its competitors with MarketBeat's FREE daily newsletter. Email Address FDMT Media Mentions By Week FDMT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. FDMT News Sentiment▼0.520.60▲Average Medical News Sentiment FDMT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. FDMT Articles This Week▼63▲FDMT Articles Average Week Get 4D Molecular Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FDMT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AVBP News COGT News OCS News BCYC News DNA News IMNM News AVDL News CVAC News CDMO News NUVB News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:FDMT) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 4D Molecular Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 4D Molecular Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free FDMT Stock Alerts